SOL Capital Management’s Lisata Therapeutics LSTA Stock Holding History

SOL Capital Management’s Portfolio LSTA Stock Details LSTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,175	Closed	-$29.3K	–	33
2026 Q1	$29.3K	Buy	+12,175	New	+$50.3K	0.01%	52

Other funds holding LSTA

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

YCM

Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

GTS Securities Miami, Florida $4.75B AUM 41.97% 1-Year Est. Return

SOL Capital Management's LSTA Position: Q2 2026 in Review

SOL Capital Management sold out of Lisata Therapeutics (LSTA) in Q2 2026, closing a stake of 12,175 shares — an estimated $29.3K sold.

SOL Capital Management first reported a position in LSTA in Q1 2026 and held it in 1 quarter. The position peaked at $29.3K in Q1 2026. 31 funds tracked by Wall St. Rank hold LSTA as of Q2 2026.

SOL Capital Management reported no remaining Lisata Therapeutics position as of Q2 2026 after selling out during the quarter.
SOL Capital Management sold 12,175 Lisata Therapeutics shares in Q2 2026, an estimated $29.3K.
SOL Capital Management first reported a position in Lisata Therapeutics in Q1 2026 and held it in 1 quarter.
SOL Capital Management's Lisata Therapeutics position peaked at $29.3K in Q1 2026.
31 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q2 2026.

Based on SOL Capital Management's 13F filing for Q2 2026.